USE OF ESTROGEN- AND PROGESTERONE-CONTAINING MEDICATIONS IN OBSTETRICS AND GYNECOLOGY
DOI:
https://doi.org/10.52340/jecm.2026.03.08Keywords:
Estrogen, Progesterone, medications, obstetrics, gynecologyAbstract
The presentation discusses important aspects of the clinical use of ovarian steroid hormones: including the principal forms of steroid hormones, their target tissues, the impact of different routes of administration on clinical outcomes. Particular attention is devoted to the evolution of the progestogen component of combined oral contraceptives (COCs), the use of high and low-dose hormonal preparations, and the principles of selective and individualized hormone selection. Cyclic and continuous combined regimens, as well as the clinical applications of selective estrogen receptor modulators (SERMs) and selective progesterone receptor modulators (SPRMs) are also reviewed. A comprehensive understanding of these aspects may facilitate a more rational, differential, and personalized approach to the use of steroid hormonal medications, thereby improving their efficacy, safety, and clinical applicability in obstetrics and gynecology.
Downloads
References
1. Bastianelli C., Farris M., et al. Pharmacodynamics of combined estrogen-progestin oral contraceptives. Part 3: Inhibition of ovulation. Expert Review of Clinical Pharmacology 2018;11(11):1085-1098.
2. Bitzer J., Amy J.J., et al. Current issues and available options in combined hormonal contraception. Contraception. 2011;84(4):342-356.
3. Damm T., Lamvu G., et al. Continuous vs cyclic combined hormonal contraceptives for treatment of dysmenorrhea: a systematic review. Contracept. X.2019;1:100002.
4. ESHRE Guideline Group on RPL. ESHRE guideline: recurrent pregnancy loss: an update in 2022.
Hum. Reprod. Open. 2023;2023(1):hoed002.
5. Evans RM., Mangelsdorf DI. Nuclear receptors, RXR, and the Big Bang.
Cell.2014;157(1):255-266
6. Fruzzetti F., Tremollieres F., et al. An overview of the development of combined oral contraceptives and their non-contraceptive benefits. European journal of contraception and Reproductive Health Care. 2021;26(1):1-13.
7. Graham S., Archer DF., et al. Review of menopausal hormone therapy with estradiol and progesterone versus other estrogens and progestins. Gynecol. Endocrinol. 2022;38(11):891-910.
8. L’Hermite M. Bioidentical menopausal hormone therapy: registered hormones (non-oral estradiol±progesterone) are optional. Climacteric. 2017;20(4):331-338.
9. Maximov P.Y., Lee T.M., et al. The discovery and development of selective estrogen receptor modulators (SERMs). Nature Reviews Drug Discovery. 2013;12:797-809.
10. Mirkin S., Komm B.S., et al. Conjugated estrogens for the treatment of menopausal symptoms: a review of safety data. Expert. Opin. Drug Saf. 2014;13(1):45-56.
11. Munro M.G., Critchley HOD., et al. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. „Int. I. Gynecol. Obstet.“ 2011;113(1):3-13.
12. North American Menopause Society. The 2022 Hormone Therapy Position Statement.
Menopause. 2022;29:767-794.
13. Panay N., Hamoda H., et al. The 2020 British Menopause Society & Women’s Health Concern recommendations on hormone replacement therapy. Post Reprod. Health. 2020;26(4):181-209.
14. Patel B., Elguero S., et al. What do we know about classical and non-classical progesterone receptors in the Human Female reproductive tract? A review. Int J of Molecular Sciences. 2021;22(22):12839.
15. Scarabin PY. Progestogens and venous thromboembolism among postmenopausal women using hormone therapy. Maturitas. 2018;115:78-82.
16. Singh S.S., Belland L., et al. The past, present and future of selective progesterone receptor modulators in the management of uterine fibroids. American J of Obstetrics and Gynecology. 2018;218:563-572.
17. Soltani A., Voedisch A.J. A review of estrogens used in menopausal hormone therapy.
Curr. Opin. Obstet. Gynecol. 2026;38(2):86-93.
18. Stanczyk FZ., Hapgood J.P., et al. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects.
Endocr. Rev. 2013;34(2):171-208.
19. Stute P., Wildt L., et al. Progestogens as a component of menopausal hormone therapy: the right molecule makes the difference. Drugs in Context. 2020;9:2020-10-1.
20. Taylor H.S., Kotlyar A.M., et al. Endometriosis is a chronic systemic disease: clinical challenges and novel innovations. The Lancet. 2021;397(10276):839-852.
21. Feede H.I., Misso M.L., et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. „Human Reproduction“, 2018;33(9):1602-1618.
22. Yildizhan R., Kurdoglu M. Progestins in combined contraceptives. Journal of Experimental and clinical Medicine. 2013;5(2):51-55.
Downloads
Published
How to Cite
Issue
Section
